There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alpha Tau Medical Ltd (DRTS – Research Report), Walgreens Boots Alliance (WBA – Research Report) and Cabaletta Bio (CABA – Research Report) with bullish sentiments.
Alpha Tau Medical Ltd (DRTS)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Alpha Tau Medical Ltd today and set a price target of $9.00. The company’s shares closed last Tuesday at $3.21, close to its 52-week low of $2.75.
According to TipRanks.com, Chen ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Alpha Tau Medical Ltd is a Moderate Buy with an average price target of $8.50, representing a 178.7% upside. In a report issued on November 17, Piper Sandler also reiterated a Buy rating on the stock with a $8.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Walgreens Boots Alliance (WBA)
J.P. Morgan analyst Lisa Gill maintained a Buy rating on Walgreens Boots Alliance yesterday. The company’s shares closed last Tuesday at $19.98, close to its 52-week low of $19.75.
According to TipRanks.com, Gill is a 5-star analyst with an average return of
Walgreens Boots Alliance has an analyst consensus of Hold, with a price target consensus of $26.13.
Cabaletta Bio (CABA)
Cabaletta Bio received a Buy rating from William Blair analyst Sami Corwin today. The company’s shares closed last Tuesday at $13.69.
According to TipRanks.com, Corwin is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cabaletta Bio with a $31.67 average price target, implying a 71.1% upside from current levels. In a report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $50.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on DRTS:
- Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer
- Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer
- Alpha Tau submits to Japanese PMDA for pre-market approval of Alpha DaRT
- Alpha Tau Medical Announces Third Quarter 2023 Financial Results and Provides Corporate Update
- Alpha Tau enters into long-term lease of site in New Hampshire
